Each Dose of Neo-Penotran® contains a combination of Metronidazole and Miconazole Nitrate in therapeutic concentrations for the local treatment of the treatment three main types of vaginal infections and mixed forms of vaginitis.

The unique combination of metronidazole and miconazole in Neo-Penotran® provides a wide spectrum of activity in the treatment of vaginitis.

Each dose of Neo-Penotran® contains 500 mg of metronidazole and 100 mg of miconazole nitrate. This dose is applied twice daily for a 7 day treatment. Each dose of Neo-penotran® Forte contains 750 mg metronidazole and 200 mg miconazole nitrate. The dose is applied once daily for a 7 day treatment. Each dose of Neo-Penotran® Forte-L contains 750 mg metronidazole and 200 mg miconazole nitrate plus 100 mg lidocaine. The dose is applied once daily for a 7 day treatment. The presence of lidocaine serves to reduce pain caused by irritation and inflammation due to vaginitis, sometimes more acute during the first 3 days of treatment. Both ingredients of Neo-Penotran®, metronidazole and miconazole nitrate, have been established as first line treatment of vaginal candidiasis, bacterial and trichomonal vaginitis. Because Neo-Penotran® contains both these ingredients, it is of clear value in the treatment of vaginitis due to any or all of the three common types of vaginitis, even when diagnosis may be uncertain. Neo-Penotran® is of special value for the immediate treatment of mixed forms of vaginitis. Clinical trials have shown Neo-Penotran® pessaries to be very well tolerated, highly effective and without significant local/systemic side effects. Neo-Penotran® pessaries may prevent secondary infection of candidal vaginitis, which may occur during therapy of metronidazole alone. A significant number of clinical trials have been carried out with Neo-Penotran® in the UK, Turkey and Turkmenistan. Results of these studies have been presented in two recent meetings of the Society of Infectious Diseases, a number of publications have appeared in the Journal of Obstetrics and Gynecology while others are still in print. Therapeutic Indications: Neo-Penotran® should be used in the treatment of vaginal candidiasis, bacterial and trichomonal vaginitis or vaginitis due to mixed infections.

Registered

Patents for Neo-Penotran® Forte-L have been applied for. Title: Anti-Vaginitis composition for topical use comprising one or more anti-vaginitis medicaments and one or more local anaesthetics. PCT/GB97/01355

Registration file in EU format available. Licensing available for selected territories other than below: Marketed in Turkey since 1994 by Embil Pharmaceutical Co. Ltd. Marketed in Singapore and Malaysia by Ranbaxy Laboratories Ltd. Marketed in Turkmenistan by Embil Pharmaceutical Co. Ltd. Marketed in Azerbaijan as "Gynotran®" by Asfarma Ltd. Marketed in the Philippines by Schering Philippine Corporation. Marketed in Vietnam by Mega Products Ltd. Marketed in Cambodia by Mega products Ltd. Marketed in Russia by Schering Russia and Ukraine by Schering Ukraine.